Title: Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia

Authors:
Sarah K. Tasian, MD *
University of California, San Francisco
Department of Pediatrics, Division of Pediatric Hematology-Oncology

* Please note current affiliation:
The Children’s Hospital of Philadelphia
Department of Pediatrics, Division of Oncology

Michelle Y. Doral, BS
University of California, San Francisco
Department of Pediatrics

Michael J. Borowitz, MD PhD
Johns Hopkins University
Department of Pathology

Brent L. Wood, MD PhD
University of Washington
Department of Laboratory Medicine

I-Ming Chen, DVM MS
University of New Mexico
Department of Pathology and UNM Cancer Center

Richard C. Harvey, PhD
University of New Mexico
Department of Pathology and UNM Cancer Center

Julie M. Gastier-Foster, PhD
The Ohio State University
Nationwide Children’s Hospital
Departments of Pathology and Pediatrics

Cheryl L. Willman, MD
University of New Mexico
Department of Pathology and UNM Cancer Center

Stephen P. Hunger, MD
Children’s Hospital Colorado and The University of Colorado School of Medicine
Department of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation
Charles G. Mullighan, MBBS MSc MD  
St. Jude Children’s Research Hospital  
Department of Pathology

Mignon L. Loh, MD **  
University of California, San Francisco  
Department of Pediatrics, Division of Pediatric Hematology-Oncology

** Author to whom correspondence should be addressed.

Dr. Mignon Loh  
University of California, San Francisco School of Medicine  
513 Parnassus Avenue, HSE 302  
San Francisco, California 94143  
lohm@peds.ucsf.edu  
Phone: 415.514.0853  
Fax: 415.502.5127

Running title: Signal Transduction in CRLF2-Rearranged ALL

Keywords: acute lymphoblastic leukemia, signal transduction, TSLP, TSLPR, CRLF2, JAK2
ABSTRACT

Adults and children with high-risk CRLF2-rearranged acute lymphoblastic leukemia (ALL) respond poorly to current cytotoxic chemotherapy and suffer unacceptably high rates of relapse, supporting the need to use alternative therapies. CRLF2 encodes the thymic stromal lymphopoietin (TSLP) receptor, which activates cell signaling in normal lymphocytes upon binding its ligand, TSLP. We hypothesized that aberrant cell signaling occurs in CRLF2-rearranged ALL and can be targeted by signal transduction inhibitors (STIs) of this pathway. In a large number of primary CRLF2-rearranged ALL samples, we observed increased basal levels of pJAK2, pSTAT5, and pS6. We thus characterized the biochemical sequelae of CRLF2 and JAK alterations in CRLF2-rearranged ALL primary patient samples via analysis of TSLP-mediated signal transduction. TSLP stimulation of these leukemias further induced robust JAK/STAT and PI3K/mTOR pathway signaling. JAK inhibition abrogated phosphorylation of JAK/STAT and, surprisingly, of PI3K/mTOR pathway members, suggesting an interconnection between these signaling networks and providing a rationale for testing JAK inhibitors in clinical trials. The PI3K/mTOR pathway inhibitors rapamycin, PI103, and PP242 also inhibited activated signal transduction and translational machinery proteins of the PI3K/mTOR pathway, suggesting that STIs targeting this pathway also may have therapeutic relevance for patients with CRLF2-rearranged ALL and merit further preclinical testing.
INTRODUCTION

B-precursor acute lymphoblastic leukemia (ALL) is a heterogeneous group of diseases whose biologic behavior is largely driven by underlying genetic mutations. Initial risk stratification of ALL according to age and white blood cell count at diagnosis can be further refined by identification of sentinel cytogenetic abnormalities.\(^1\) Therapy intensification for high risk genetic subgroups has dramatically improved event-free survival over the past 50 years.\(^2\) However, approximately 25-30\% of children have no known cytogenetic abnormality,\(^3\) and that percentage is even greater in adults with ALL.\(^4\) Currently, 80-85\% of children and 35-50\% of adults with ALL are cured with modern multi-agent therapeutic regimens,\(^1,2,4,5\) but most patients who fail treatment will die.\(^6\) Identification of those patients who will ultimately relapse is thus a priority for basic and clinical investigators who seek discoveries that will lead to new therapies.\(^7\)

Genomic profiling efforts using high-density single nucleotide polymorphism genotyping and gene expression profiling (GEP) conducted by collaborative research groups in Europe and Israel and by the Children’s Oncology Group (COG) via the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative of the National Cancer Institute (NCI) have recently identified novel gene alterations in high risk adult and childhood ALL, including mutations in \textit{CRLF2} (cytokine receptor-like factor 2),\(^8,9\) members of the JAK family of kinases (\textit{JAK1} and \textit{JAK2}),\(^11-14\) and the IL-7 receptor alpha chain (IL-7R\(\alpha\); \textit{IL7RA}).\(^15\) JAK point mutations and \textit{CRLF2} alterations have been described in 60\% of Down syndrome (DS)-associated ALL.\(^9,11-14,16-18\)

\textit{CRLF2} alterations occur in up to 8\% of unscreened childhood B-precursor ALL cases, in up to 15\% of high risk (HR) B-precursor ALL patients as defined by the Oxford Hazard Score (OHS) or the NCI-Rome risk criteria (age > 10 years and/or white blood cell count > 50,000/uL),
and in approximately 15% of adult B-precursor ALL patients. We and others have observed that NCI HR patients with CRLF2-rearranged (CRLF2) ALL have high rates of minimal residual disease (MRD) measured by flow cytometry or PCR-based strategies at the end of induction chemotherapy. Retrospectively analyzed clinical studies note high rates of relapse and/or poor overall survival (OS) in NCI or OHS HR children and adults with CRLF2, ALL, but an intermediate prognosis in standard risk (SR) patients. Further biologic studies may facilitate the identification of factors contributing to these discrepant clinical outcomes, as well as provide additional rationale for the development of new therapies with potentially fewer toxicities, especially for patients (e.g., adults) who are unable to tolerate traditional genotoxic chemotherapy.

Several alterations in CRLF2 resulting in its overexpression have been described in ALL: a focal ~320 kilobase interstitial deletion of the pseudoautosomal region of the sex chromosomes (Xp22.23 or Yp11.32) that creates a fusion of CRLF2 to the G-protein-coupled purinergic receptor P2RY8 gene (P2RY8-CRLF2), translocation of CRLF2 to immunoglobulin heavy chain transcriptional enhancers (14q32.3; IGH@-CRLF2), and a point mutation in CRLF2 resulting in a phenylalanine-to-cysteine substitution at amino acid 232 (F232C). Approximately 50% of CRLF2 ALLs also harbor JAK mutations, the most common of which gives rise to the ALL-specific JAK2 R683G alteration located in the JH2 pseudokinase domain, while virtually all cases with JAK mutations have concomitant CRLF2 alterations. Concurrent IKZF1 mutations also occur frequently, and IL7RA mutations were recently reported in a small number of CRLF2 B-precursor ALL cases.

CRLF2 normally heterodimerizes with the IL-7Rα chain (also known as CD127) and binds its ligand, TSLP, an important physiologic signal for normal lymphopoiesis and for
mediation of allergy and inflammation.\textsuperscript{25-27} Binding of TSLP to the TSLP receptor complex (TSLPR) activates STAT5 through currently unknown mechanisms, but likely involves phosphorylation of JAK2 (pJAK2).\textsuperscript{26,28-30} Brown \textit{et al.} initially demonstrated murine TSLP-induced phosphorylation of STAT5, S6, and 4EBP1 in B-precursor ALL cell lines established from E\textsubscript{μ}-RET transgenic mice.\textsuperscript{31,32} More recently, several groups in Europe and in the United States have observed constitutive and/or inducible phosphorylation of STAT5, S6, and/or ERK in Ba/F3 (murine pro-B cell lymphoma) cell lines transduced with human ALL-specific JAK and/or \textit{CRLF2} mutations, as well as inhibition of JAK/STAT signal transduction with chemical JAK inhibition or heat shock protein 90 (HSP90) inhibition.\textsuperscript{9,11,14-16,22,33,34}

These data raise the possibility that multiple signaling cascades play a role in these leukemias. We hypothesized that \textit{CRLF2} rearrangements in primary human ALL result in perturbed signaling networks beyond the expected JAK/STAT signaling axis and thus sought to determine the phosphorylation status of intracellular signaling proteins in two human \textit{CRLF2} ALL cell lines, 46 \textit{CRLF2} ALL patient samples without and with JAK point mutations (JAK\textsubscript{mut}), and 33 \textit{CRLF2}-wild type/JAK-wild type (CRLF2\textsubscript{wt}/JAK\textsubscript{wt}) patient samples following cytokine stimulation or exposure to signal transduction inhibitors (STIs). We demonstrated increased basal levels of pJAK2, pSTAT5, and pS6 and enhanced TSLP-mediated signal transduction via the JAK/STAT and PI3K/mTOR pathways only in the \textit{CRLF2} ALL samples and could inhibit aberrant signaling \textit{in vitro} with specific small molecule inhibitors of these pathways.
MATERIALS AND METHODS

Cell Culture. The human B-precursor ALL cell lines MUTZ5, MHH-CALL-4, RCH-ACV, and REH were purchased from the DSMZ (Braunschweig, Germany). MUTZ5 overexpresses CRLF2 via an IGH@-CRLF2 translocation and has a JAK2 R683G mutation. MHH-CALL-4 has an IGH@-CRLF2 translocation and a JAK2 I682F mutation. RCH-ACV and REH are CRLF2wt B-precursor ALL cell lines with a t(1;19) and a t(12;21), respectively, that were used as negative controls. Cell lines were maintained in RPMI with fetal bovine serum (FBS) and penicillin/streptomycin/glutamine in a 37 °C incubator with 5% CO2 and harvested in the logarithmic phase of growth with >95% viability.

Patient Samples and Characteristics. We analyzed a total of 79 cryopreserved or fresh pre-treatment primary ALL samples in a series of experiments, 46 of which had CRLF2 genomic alterations and 33 ALL samples that did not have CRLF2 rearrangements (Table 1 and Supplemental Table 1). Pre-treatment leukemia samples were obtained from trials sponsored by the St. Jude Children’s Research Hospital (SJCRH) and the Children’s Oncology Group (COG) under institutional review board approval. Informed consent for tissue banking and research studies was obtained from patients and/or their guardians according to the Declaration of Helsinki. Patients were classified as NCI SR or HR based upon diagnostic clinical data. Thirty-two cryopreserved ALL samples were obtained from the SJCRH Tissue Bank (Memphis, TN) and the COG Tissue Bank (Nationwide Children’s Hospital; Columbus, OH). The SJCRH samples had been previously identified as CRLF2 overexpressors by gene expression analyses and subsequently characterized for specific CRLF2 and JAK alterations. Cells were thawed quickly, washed, and then assessed for post-thaw cell counts and viability with a Vi-Cell analyzer (Beckman Coulter; Miami, FL). Forty-seven (20 without and 27 with increased
TSLPR) fresh ALL samples were obtained from the COG Core Flow Cytometry Laboratories at the Johns Hopkins University (Baltimore, MD) and the University of Washington (Seattle, WA), then submitted for phosphoflow cytometry analysis and for mutation testing. Mononuclear cell layers containing the ALL cells were isolated via standard density centrifugation. Six cryopreserved and three fresh samples were excluded from the phosphosignaling analyses because they did not meet the pre-determined criterion of at least 25% shift of cells with the pervanadate positive control condition. Thus 70 of the 79 cryopreserved or fresh leukemia samples were included in the final analyses.

**Polymerase Chain Reaction (PCR).** DNA and RNA were extracted from isolated leukemia cells per standard methods. PCR was performed using previously described cycling conditions and primers for JAK1 exons 13 and 14,14 JAK2 exons 16, 20, and 21,12,14 CRLF2 exon 6,22 and IL7RA exons 5 and 6.15 SuperScript III (Invitrogen) cDNA synthesis was performed per product instructions prior to RT-PCR for the P2RY8-CRLF2 fusion.9 Sanger sequencing was performed by Quintara Biosciences (Berkeley, CA) or by the Hartwell Center at SJCRH (Memphis, TN). Mutations were analyzed using Geospiza FinchTV version 1.4 software (Seattle, WA).

**Fluorescence In Situ Hybridization (FISH).** Leukemia cell pellets were prepared in Carnoy’s fixative. FISH analyses to detect rearrangement and structural alterations of IGH® and CRLF2 were performed as previously described.10

**Western Blotting.** MUTZ5 cells were rested in serum-free media for 16 hours in IMDM with 1% BSA at 37 °C, then incubated with 0.1% dimethyl sulfoxide (DMSO) as a negative control or with signal transduction inhibitors (STIs) for 30 minutes at 37 °C: the JAK1/JAK2 inhibitor ruxolitinib (1 uM; Incyte), the mTOR inhibitor rapamycin (10 nM; Calbiochem), the dual
PI3K/mTOR inhibitor PI103 (1 μM), the mTORC1/mTORC2 inhibitor PP242 (1 μM), or the MEK inhibitor PD901 (1 μM; Pfizer). Some cells were subsequently stimulated with recombinant human TSLP (25 ng/mL; R&D Systems) for an additional 30 minutes at 37 °C. For non-inhibitor conditions, cells were stimulated with TSLP for 30 minutes at 37 °C. Pervanadate (125 μM; prepared from sodium orthovanadate and 3% hydrogen peroxide; Sigma), an irreversible protein tyrosine phosphatase inhibitor, was also used as a positive control to elicit maximal phosphorylation of each signaling protein. Cells were immediately lysed in NP-40 cell lysis buffer (Invitrogen) supplemented with 1% protease and phosphatase inhibitors (Calbiochem). Lysates were separated via SDS-PAGE and immunoblotted on to nitrocellulose for probing with antibodies against total and phosphorylated (p) proteins STAT5, ERK 1/2, Akt, S6, 4EBP1, and eIF4E and against β-actin. Antibodies were from Cell Signaling Technologies (STAT5, pSTAT5 Y694, ERK, pERK T42/44, Akt, pAkt S473, S6, pS6 S235/236, 4EBP1 and p4EBP1 T37/46, eIF4E, and β-actin) and Invitrogen (pEIf4E S209).

**Phosphoflow Cytometry.** MUTZ5 cells and primary patient samples were prepared as described above, rested without serum for 16 hours (MUTZ5) or 1 hour (patient samples) at 37 °C, and exposed to the identical series of agents at the same timepoints and concentrations as described above. Some samples were also incubated with the JAK2 inhibitor XL019 (1 μM; Exelixis) for 30 minutes at 37 °C. The pervanadate exposure was used to delineate the potential dynamic signaling ranges and to identify subsets of cells that did not shift. Following inhibition and/or stimulation, samples were immediately fixed with paraformaldehyde (Electron Microscopy Services) and permeabilized with ice-cold methanol (Electron Microscopy Services) per published methods.36 Samples were then stained with surface and/or phosphoprotein antibodies against human CD3, CD10, CD19, TSLPR, CD127, pSTAT5, pERK, pAkt, pS6,
p4EBP1, and peIF4E prior to analysis on a Becton-Dickinson LSRII flow cytometer. CRLF2r and CRLF2wt (control) ALL samples were gated upon CD3- CD10+ CD19+ TSLPR+ cells and CD3- CD10+ CD19+ cells, respectively, for phosphosignaling analyses. For cell line surface staining experiments, fluorescence-minus-one controls for each cell line were used. Antibodies were from BD Biosciences (CD3-Ax700 or -Pacific Blue, CD10-PE-Cy7, CD19-Ax700 or -APC-Cy7, CD127-Ax647, pSTAT5Y694-Ax647, pERK^T42/44-Ax647, pAkt^S473-Ax488 or -V450, pS6^S235/236-Ax488 or -V450, and isotype controls), Cell Signaling Technologies (unconjugated pS6^S235/23 and p4EBP1^T37/46), Invitrogen (unconjugated peIF4E^S209 and Pacific Blue-conjugated secondary donkey anti-rabbit IgG), EBioscience (TSLPR-PE or -PerCP-eFluor-710 clone 1A6, CD127-FITC, CD132-PE), and Jackson Immunology (FITC-conjugated secondary donkey anti-rabbit IgG and goat anti-rat IgG). Data were analyzed via FlowJo (TreeStar; Ashland, OR) and Cytobank (Palo Alto, CA) software.

**Proliferation and Cytotoxicity Assays.** MUTZ5, MHH-CALL-4, RCH-ACV, and REH cells were incubated with media or increasing concentrations of TSLP (proliferation assays) or with DMSO or increasing concentrations of ruxolitinib, PI103, PP242, PD901, or ruxolitinib and rapamycin (cytotoxicity assays) in 96-well plates for 72 hours. Methylthiazole tetrazolium (MTT) assays were performed as previously described. Experiments were performed in triplicate three times.

**Statistical Analyses.** Digital phosphoflow cytometry data were recorded as raw data, as well as transformed with the inverse hyperbolic sine (arcsinh) equation via Cytobank (Palo Alto, CA) to display and compare intensity values and to correct for large variances of some fluorophores. Data were then reported as the 75% percentile to minimize confounding effects of viable primary leukemia cells that signaled incompletely to pervanadate, then normalized to the basal
phosphorylation levels for each patient sample for data display. Individual patient sample data were displayed as whisker plots via Prism (GraphPad Software; La Jolla, CA). The distribution of patient sample data was tested and confirmed to be non-Gaussian. The two-tailed Mann-Whitney U test with alpha = 0.05 was thus used to assess differences between the phosphorylation levels of basal states to those of the stimulation or inhibition conditions or between TSLP stimulation and STI with TSLP stimulation conditions. Data from MTT assays were displayed as bar graphs of mean data with standard deviations using Prism.

RESULTS

Patients with CRLF2-r ALL can be rapidly identified by flow cytometry. We first confirmed that primary CRLF2-r ALL samples have increased surface levels of the TSLPR subunit, even in primary cells that had been fixed and permeabilized for phosphoflow cytometry analysis. The level of increased TSLPR staining was similar among leukemias with P2RY8-CRLF2, IGH@-CRLF2, and CRLF2 F232C (representative samples in Figure 1A). CD3-CD10+ CD19+ CRLF2-r ALL samples were thus identified for these studies via their increased TSLPR staining in comparison to an isotype control (Supplemental Figure 1). The presence or absence of a concomitant JAK or IL7RA mutation was not associated with changes in TSLPR surface staining (data not shown).

Surface staining of the IL-7Rα chain (CD127), the other subunit of the heterodimeric TSLPR, did not differ appreciably among CRLF2-r (N = 17) and CRLF2wt (N = 24) ALL samples (representative data in Figure 1A). Analysis of MUTZ5 and MHH-CALL-4 demonstrated intermediate CD127, bright TSLPR, and dim-to-intermediate CD132 (the common γ chain, which associates with IL-7Rα to form the IL-7R) staining in contrast to RCH-ACV and REH, suggesting the possibility of preferential association of the IL-7Rα chain with the TSLPR
subunit in CRLF2, ALL cells (Figure 1B and Supplemental Figure 2). Isotype-stained normal mature human B-lymphocytes and CD127- and CD132-stained normal T-lymphocytes from peripheral blood were used as negative and positive controls, respectively (Supplemental Figure 2).

**TSLP, but not IL-7, induces growth and signaling in CRLF2, ALL.** In proliferation assays, we observed TSLP dose-dependent increased proliferation in MUTZ5 and MHH-CALL-4 cells, but not in RCH-ACV or REH (Figure 1C and Supplemental Figure 3). In phosphoflow assays, *in vitro* stimulation of MUTZ5 cells and primary CRLF2, ALL cells with TSLP induced dose-dependent increases in STAT5 phosphorylation (N = 4; representative sample in Figure 1D). The 25 ng/mL TSLP concentration was selected for subsequent studies, which is concordant with concentrations used in other studies.\(^{27,40}\) TSLP stimulation of MUTZ5 robustly induced pJAK2 and pSTAT5 (Figure 2A and Supplemental Figure 4). We did not observe increased TSLP-induced pSTAT1, pSTAT3, or pSTAT6 in MUTZ5, MHH-CALL-4, or 3 primary CRLF2, ALL samples (data not shown). TSLP stimulation also robustly induced pS6 and slightly increased pERK. PSTAT5 and pS6 were inhibited below basal levels by the JAK2-specific inhibitor XL019. Incubation of MUTZ5 or MHH-CALL-4 with IL-7 had no effect upon pSTAT5, pS6, or pERK, which confirmed that IL-7 is not a ligand for the TSLPR (Figure 2A and Supplemental Figure 5). In peripheral blood samples, we confirmed that IL-7 stimulation had no effect upon CRLF2, primary ALL cells, but did induce pSTAT5 in CD3+ T cells of these patients, which provided a critical internal positive control (N = 12; representative sample in Supplemental Figure 6).

In our initial analyses of CRLF2<sub>wt</sub> and CRLF2<sub>r</sub> ALL patient samples, we observed higher basal levels of pJAK2, pSTAT5, and pS6 in samples with CRLF2 rearrangements than in those
without rearrangements (p < 0.05 for all subgroups; Figure 2B). Based upon the TSLP-inducible signaling we had observed in MUTZ5 and MHH-CALL-4, we hypothesized that in vitro TSLP stimulation would induce similar phosphorylation patterns in CRLF2, ALL patient samples. TSLP increased pSTAT5 and pS6 in the CRLF2, ALL cells regardless of JAK point mutation status (CRLF2, JAKwt, N = 14; CRLF2, JAKmut, N = 10) (p < 0.05 for all subsets), but had no effect on CRLF2wt ALL (N= 17) (Figure 2C). This phenomenon suggests that CRLF2 alterations are the main genetic event driving aberrant signal transduction. Interestingly, unlike in MUTZ5 and MHH-CALL-4, TSLP induced minimal pERK in the primary patient samples. As expected, IL-7 had no effect on pSTAT5, pS6, or pERK in the CRLF2, ALL patient samples. XL019 inhibited pS6 below basal levels in the CRLF2, JAKmut group (p = 0.013), but not in the CRLF2, JAKwt or CRLF2wt JAKwt groups, and did not significantly inhibit pSTAT5 below basal levels in any of the three groups. Incubation of CRLF2wt JAKwt ALL cells with TSLP or IL-7 stimuli or inhibition with XL019 had no effect on any phosphoprotein examined (Figure 2C).

**TSLP stimulation induces phosphorylation of multiple PI3K/mTOR pathway members, which can be abrogated by STIs.** After we observed that TSLP stimulation of CRLF2, ALL cells also induces pS6, we then examined the phosphorylation status of other PI3K/mTOR pathway proteins, including Akt and the translational machinery proteins 4EBP1 and eIF4E, in MUTZ5 cells (Figure 3A). In addition to increases in pSTAT5, pS6, and pERK, TSLP stimulation of MUTZ5 also induced pAkt, p4EBP1, and peIF4E (Figure 3B and Supplemental Figure 4). In addition to testing the JAK1/JAK2 inhibitor ruxolitinib and the MEK inhibitor PD901, we also tested the effects of several PI3K/mTOR pathway STIs (rapamycin, PI103, PP242) to delineate more precisely the role and potential interaction of the PI3K/mTOR, JAK/STAT, and Ras/MAPK pathways in TSLPR-mediated signaling (Figure 3A). Given our
surprise that CRLF2, ALL cells were able to respond to in vitro TSLP stimulation, we then asked if a “rescue” stimulation with TSLP could overcome the effects seen with inhibitors alone. Ruxolitinib inhibited pSTAT5, pAkt, pS6, and p4EBP1, which were not overcome by subsequent TSLP stimulation. As expected, there was no significant effect of rapamycin, PI103, or PP242 on pSTAT5, but pS6, p4EBP1, and (to a lesser degree) p-eIF4E were inhibited. Subsequent TSLP exposure partially rescued inhibition of pS6, while sustained inhibition was observed for p4EBP1. PD901 most appreciably inhibited pS6, and TSLP did not rescue cells from this pS6 inhibition (Figure 3B). These signaling phenomena were similarly recapitulated in MHH-CALL-4 (Supplemental Figure 5).

We validated the phosphoflow cytometry results in MUTZ5 cells via Western blotting (Figure 3C). TSLP stimulation evoked phosphorylation of all examined phosphoproteins, including an increase in pERK. This induction of pERK was seen by phosphoflow cytometry to a lesser degree than by immunoblotting, which was most likely attributable to the different sensitivities of the antibodies used for each technique. In addition, the phosphoflow cytometry results are depicted as induced or inhibited signaling normalized to respective basal phosphorylation to visualize the dynamic signaling ranges above and below basal levels, respectively, whereas the Western blotting data are displayed independently as basal and induced or inhibited levels of phosphorylation. We also observed constitutively high basal p4EBP1 and total eIF4E levels via immunoblotting, which may account for the smaller increases in TSLP- or pervanadate-induced phosphorylation in comparison to other examined phosphoproteins. TSLP stimulation induced p-eIF4E and a slight increase in total 4EBP1 protein (but not p4EBP1), suggesting active protein translation and near-maximal phosphorylation of 4EBP1. Ruxolitinib shut down basal and TSLP-induced pSTAT5, pAkt, pS6, p-eIF4E, and pERK. Cells exposed to
rapamycin, PI103, or PP242 demonstrated inhibition of pS6 and p4EBP1 with PP242 achieving the most potent and sustained inhibition. As observed in the phosphoflow cytometry assay (Figure 3B), rescue TSLP exposure partially overcame the rapamycin, PI103, and PP242-induced inhibition of pS6, but not the PI103- or PP242-induced inhibition of pAkt or the PD901-induced inhibition of pERK or pEIF4E (Figure 3C). Rapamycin had no effect upon pAkt.

Growth of CRLF2<sub>r</sub> ALL cell lines is inhibited by STIs. To assess the biologic effects of the STIs, we measured STI-induced cytotoxicity in short-term culture of ALL cell lines via MTT assay (Figure 3D and Supplemental Figure 7). Dose-dependent cytotoxicity was observed with the STIs in all cell lines studied. Inhibition by ruxolitinib was modestly more pronounced in MUTZ5 and MHH-CALL-4 compared to RCH-ACV and REH, while rapamycin resulted in greater cytotoxicity in RCH-ACV and REH. The combination of ruxolitinib and rapamycin at 500 and 1000 nM resulted in a mild increased cytotoxicity in MUTZ5 and MHH-CALL-4 (Figure 3D and Supplemental Figure 7).

JAK/STAT and PI3K/mTOR STIs inhibit signal transduction preferentially in CRLF2<sub>r</sub> ALL patient samples. Based upon our initial observations in cell lines and in primary ALL samples, we then examined our extended STI panel in an additional 7 CRLF2<sub>wt</sub> and 22 CRLF2<sub>r</sub> ALL samples. CRLF2<sub>r</sub> JAK<sub>wt</sub> and CRLF2<sub>r</sub> JAK<sub>mut</sub> samples were grouped for this analysis. No effects of the STIs were observed in the CRLF2<sub>wt</sub> samples with the exception of inhibition of pAkt, p4EBP1, and pEIF4E by PP242 (p < 0.05; Figure 4A). As predicted, stimulation with TSLP induced pSTAT5, pAkt, pS6, p4EBP1, pEIF4E, and pERK (p < 0.05 for all conditions) in the CRLF2<sub>r</sub> group (Figure 4B). Conversely, in the CRLF2<sub>r</sub> samples, ruxolitinib inhibited all six phosphoproteins examined (p < 0.05), and this inhibition was sustained despite subsequent TSLP stimulation. PI103 and PP242 inhibited TSLP-induced pAkt (p < 0.05). Similar to the MUTZ5
cells analyzed by Western blotting, the PI3K/mTOR pathway STIs and PD901 induced sustained inhibition of pS6 (p < 0.05), although TSLP restored p4EBP1 in rapamycin-, PI103-, PP242-, and PD901-exposed cells (Figure 4B).

**DISCUSSION**

Our analyses are the first to provide biochemical characterization of the signaling consequences of *CRLF2* rearrangements in a substantial cohort of primary human B-precursor ALL samples and highlight the potential utility of STI-based therapies for these patients. We observed basal activation of JAK/STAT and PI3K/mTOR signaling in CRLF2r ALL, as well as induced phosphorylation with TSLP stimulation of cell lines and primary patient samples. TSLP also increased proliferation of CRLF2r ALL cell lines, but not of CRLF2wt cell lines, in short-term culture. We further observed inhibition of aberrant JAK/STAT signaling *in vitro* by the JAK inhibitors XL019 and ruxolitinib and, intriguingly, suppression of S6 phosphorylation by JAK inhibition. While the inhibition of pS6 by XL019 and ruxolitinib cannot exclude the possibility of off-target effects, we hypothesize that these data reflect interconnections between the JAK/STAT and PI3K/mTOR signaling networks given the increased Akt, S6, 4EBP1, and eIF4E phosphorylation in response to TSLP stimulation.41,42 We further explored the involvement of the PI3K/mTOR network via expanded phosphoflow cytometry analyses of cell lines and primary patient samples with rapamycin, PI103, and PP242. These STIs, particularly PP242, inhibited pAkt, pS6, p4EBP1, and/or p.eIF4E, suggesting that PI3K/mTOR pathway STIs may be an additional therapeutic strategy for patients with CRLF2r ALL. In MTT assays, ruxolitinib preferentially inhibited cell growth of the CRLF2r ALL cell lines, and incubation with PI3K/mTOR STIs also resulted in dose-dependent cytotoxicity.
Our results are generally concordant with those of other preclinical studies, although some differences exist. Although one study reported TSLP-induced cellular proliferation and induction of pSTAT5, pS6, and p4EBP1 in murine (presumably non-CRLF2-rearranged) B-precursor ALL cell lines and rapamycin-induced inhibition of pS6 and p4EBP1, we did not detect significant biochemical effects of IL-7, TSLP, or rapamycin in the 33 primary non-CRLF2, ALL samples in our studies. Murine and human TSLP share approximately 43% sequence homology, however, and our discordant results may reflect inherent biologic differences of TSLP-mediated signaling in normal and malignant lymphopoiesis in mice versus humans. In addition, IL-7 is required for murine B cell maintenance and growth, while the necessity of IL-7 in human B progenitor cell development remains less well-delineated. Recent studies using Ba/F3 cells transduced with various ALL patient-derived CRLF2 and JAK mutations demonstrated constitutive and TSLP-inducible JAK/STAT signal transduction and cellular proliferation that could be abrogated by in vitro chemical JAK inhibition. Some groups also observed increased pS6 and/or pERK in some Ba/F3 cells transduced with ALL-specific CRLF2 and/or IL7RA mutations. Work by our group and by others thus demonstrates perturbed TSLP-induced JAK/STAT and PI3K/mTOR signal transduction in primary human CRLF2, ALL samples and the ability to inhibit these signaling networks via targeted inhibitors. Our STI data also suggest an interconnection between JAK/STAT and PI3K/mTOR signaling, though additional work is necessary to elucidate fully this connection. Although we were easily able to interrogate multiple surface markers and phosphoproteins in these studies, utilization of more sophisticated flow cytometry technologies currently in development and conjugation of phospho-antibodies to additional distinguishable fluorochromes will greatly expand the scope of our ongoing studies.
Based upon our findings, we suggest that TSLPR surface staining could be included in routine clinical immunophenotyping for identification of most newly-diagnosed patients with CRLF2r ALL for swift treatment with STI-based therapies. Determination of the absence or presence of the TSLP-mediated phosphosignaling signature may be of particular diagnostic utility for TSLPR-dim samples with results obtainable within 24-48 hours of sample submission, but such approaches would require careful validation in clinical laboratory settings.

It is important to note the limitations of our in vitro studies. Primary patient samples are inherently heterogeneous, although most of the analyzed samples were from diagnostic bone marrow specimens and were generally comprised of > 90% leukemia cells with uniform surface staining. Because some samples had been cryopreserved and thawed, while the fresh samples were approximately 48 hours old at time of processing due to unavoidable transit times, we gated upon the live B-precursor lymphoblasts and used pervanadate as a positive control to ensure functional signaling of each sample, as conventional propidium iodide staining to identify dead cells is not feasible in permeabilized cells. In addition, although optimized antibody cocktails and flow cytometer settings were standardized, we analyzed two to six samples per individual experiment based upon availability of clinical samples and cannot exclude the possibility of minor experiment-to-experiment variability, although we did include MUTZ5 cells as a positive control cell line in each experiment. For this reason, we normalized the phosphorylation levels of each patient sample to its own basal levels for measurements of response to stimulation or inhibition.

In concordance with preclinical models, we observed constitutive activation of JAK/STAT and PI3K/mTOR signaling in primary ALL samples with CRLF2 rearrangements (Figure 2B). Although our study was not powered to detect potential signaling differences
between the P2RY8-CRLF2 and IGH@-CRLF2 subgroups, we also noted a trend of higher basal levels of some phosphoproteins in some leukemia samples (e.g., 0.5-1 log-fold higher basal pS6 for several IGH@-CRLF2 translocation samples than observed for P2RY8-CRLF2 fusion samples). The lack of obvious basal or TSLP-induced signaling differences between the CRLF2r JAKwt and the CRLF2r JAKmut groups remains unsolved, however. Additional studies are ongoing to assess potential genetic differences among these subgroups. Further, while we observed TSLP-inducible signaling in vitro, we do not know whether patients with CRLF2r ALL have elevated TSLP cytokine levels in vivo, which will require evaluation in future studies.

In summary, adults and children with NCI or OHS HR CRLF2r ALL treated with current regimens have unacceptably high rates of relapse, and new therapies are needed to improve clinical outcomes. These analyses are the first to our knowledge to begin to characterize the biochemical sequelae of CRLF2 rearrangements in primary human ALL patient samples. Our phosphoflow cytometry assays allowed simultaneous measurement of multiple phosphoproteins in small numbers and in heterogeneous subpopulations of primary leukemia cells. We demonstrated aberrant TSLP-mediated JAK/STAT and PI3K/mTOR pathway signal transduction in primary human CRLF2r ALLs, as well as the ability to inhibit these signaling networks with targeted STIs. Specifically, JAK inhibition was able to suppress both pathways, supporting the potential clinical utility of these agents. Our data provide rationale for further evaluation of these agents in pre-clinical and, eventually, clinical testing. Via identification of the specific perturbed signaling network(s) involved in individual leukemia samples, such assays may facilitate future selection of pertinent, tailored STI-based therapies. Precedent exists for the addition of STIs for treatment of pediatric leukemias, as evidenced by the dramatic improvement in OS for children with BCR-ABL1-positive ALL when imatinib was added to systemic chemotherapy.49
Additional studies are ongoing to assess the cytotoxic effects of JAK and PI3K/mTOR pathway STIs without and with conventional chemotherapy agents in short-term cultures of CRLF2, ALL primary samples. Results from these studies, as well as safety data from children with relapsed or refractory malignancies treated with ruxolitinib on the COG Phase I trial ADVL1011, will likely facilitate the identification of potentially efficacious STIs for adults and children with CRLF2, ALL and will inform the development of subsequent clinical trials for these patients.
ACKNOWLEDGEMENTS

The authors thank Dr. Douglas Clary (Exelixis) for providing XL019, Dr. Jordan Fridman (Incyte) for providing ruxolitinib, and Dr. Kevan Shokat (University of California, San Francisco) for providing PI103 and PP242. The authors acknowledge Ms. Karen Bowles and Ms. Stacey Middleditch at Johns Hopkins University and Ms. Eileen Stonerock at Nationwide Children’s Hospital for assistance with patient sample acquisition. The authors are grateful to the patients and their families for consenting to tissue banking and research studies. The authors also acknowledge Drs. Jonathan Irish and Nikesh Kotecha at Stanford University for assistance with Cytobank and Dr. Martin Carroll at the University of Pennsylvania for critical review of the manuscript. Funding for this work was provided by NIH training grants 5T32HD044331, 1T32CA128583, and K12CA076931 (SKT), NCI U10 CA098543 (COG, Chair’s Award) and a supplement to that grant to support the TARGET Project, NCI GO 5RC2 CA14852902 (Targeted Therapies for Childhood Acute Lymphoblastic Leukemia: Translating Discovery into Practice), U10 CA98413 supporting the COG Statistical Center, U24 CA114766 supporting human specimen banking in NCI-supported cancer trials, a Conquer Cancer Foundation/American Society of Clinical Oncology Young Investigator Award (SKT), the TeamConnor Childhood Cancer Foundation (SKT), and the St. Baldrick’s Foundation (MLL). CLW is the Maurice and Marguerite Liberman Chair in Cancer Research. SPH is the Ergen Family Chair in Pediatric Cancer. CGM is a Pew Scholar in the Biomedical Sciences and a St. Baldrick’s Scholar. MLL is a Clinical Scholar of the Leukemia and Lymphoma Society.
AUTHORSHIP CONTRIBUTIONS

SKT designed research, performed experiments, analyzed and interpreted data, and wrote the manuscript; MYD performed experiments and analyzed data; MJB, BLW, JMG-F, SPH, and CGM provided patient samples and interpreted data; IMC and RCH performed experiments and analyzed data; CLW interpreted data; MLL designed research, interpreted data, and wrote the manuscript. All authors critically reviewed the final manuscript prior to submission.

DISCLOSURE OF CONFLICTS OF INTEREST

MLL is a member of the Data Safety and Monitoring Committee for the Bristol-Myers Squibb clinical trial CA180226. None of the other authors has a conflict of interest to declare.
REFERENCES


23


Table 1. *CRLF2*, *JAK*, and *IL7RA* mutation status of 79 patients with B-precursor ALL whose leukemias were analyzed by phosphoflow cytometry.

<table>
<thead>
<tr>
<th>CRLF2 Rearrangement</th>
<th>JAK Mutation</th>
<th>IL7RA Mutation</th>
<th>Number of Samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>No</td>
<td>No</td>
<td>33</td>
</tr>
<tr>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>32</td>
</tr>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>14</td>
</tr>
</tbody>
</table>
FIGURES

Figure 1. Surface marker, proliferation, and intracellular signal transduction analyses of human CRLF2r and CRLF2wt leukemias.

A. Flow cytometry analysis of primary human CRLF2r and CRLF2wt ALL samples (N = 70; 4 representative samples shown) for the TSLPR and the IL-7Rα chain (CD127). CD10+ CD19+ ALL cells with CRLF2 alterations demonstrated increased surface staining of the TSLPR regardless of the mechanism of CRLF2 rearrangement. No increased TSLPR staining was observed for leukemias without CRLF2 alterations. CD127 staining was similar in CRLF2r and CRLF2wt ALL cells. Shaded histogram = isotype control. Open histogram = stained cells.

B. Surface marker analysis of human B-precursor CRLF2r JAKmut ALL cell line MUTZ5 and CRLF2wt JAKwt cell line RCH-ACV. MUTZ5 cells stained uniformly for TSLPR, but were intermediate for CD132 (the common γ chain). RCH-ACV demonstrated bright CD127, absent TSLPR, and intermediate-to-bright CD132, suggesting the presence of the normal heterodimeric IL-7R.

C. Incubation of cells with human TSLP for 72 hours resulted in dose-dependent proliferation of MUTZ5, but not of RCH-ACV, measured by MTT assay. Red = 1 ng/mL, yellow = 10 ng/mL, green = 25 ng/mL, blue = 100 ng/mL of TSLP. Data are normalized to the medium-only condition at 72 hours for each cell line.

D. Primary CRLF2r, ALL cells were exposed to increasing concentrations of human TSLP for 30 minutes, then fixed and permeabilized for flow cytometric analysis of pSTAT5. Near-maximal STAT5 phosphorylation was elicited with 25 ng/mL of TSLP, the concentration used in the in vitro studies.
Figure 2. Constitutive and TSLP-inducible JAK/STAT and PI3K/mTOR signaling occurs in CRLF2r ALL.

A. Stimulation of MUTZ5 cells with IL-7 had no effect upon JAK2, STAT5, S6, or ERK phosphorylation, as measured by phosphoflow cytometry. Stimulation with TSLP induced phosphorylation of pJAK2, pSTAT5, pS6, and, to a lesser extent, pERK. The JAK2-specific inhibitor XL019 inhibited pSTAT5 and pS6. Pervanadate was used as a positive control for measurement of maximal phosphorylation. Individual histograms are also displayed as a heatmap for ease of comprehensive data visualization. Data were normalized to the basal phosphorylation level of each protein for colorimetric depiction of signaling changes. Blue = inhibition and yellow = stimulation.

B. Basal levels of phosphorylation of JAK2, STAT5, S6, and ERK in primary CRLF2wt JAKwt (white bars; N = 27), CRLF2r JAKwt (light grey bars; N = 29), and CRLF2r JAKmut (dark grey bars; N = 14) were measured by phosphoflow cytometry, and median fluorescent intensity (MFI) was calculated for each phosphoprotein. Data are displayed as whisker plots of 25th to 75th percentiles with means (central bars) and ranges (whiskers). PJAK2, pSTAT5, and pS6 were significantly elevated in the CRLF2r JAKwt and CRLF2r JAKmut samples in comparison to levels of the CRLF2wt JAKwt samples. *** = p <0.0005, ** = p <0.005, * = p <0.05. Non-CRLF2-rearranged JAK wild-type = CRLF2wt JAKwt, CRLF2-rearranged JAK wild-type = CRLF2r JAKwt, CRLF2-rearranged JAK mutant = CRLF2r JAKmut.

C. Phosphoflow cytometry analysis of 41 primary human ALL samples without and with CRLF2 alterations and JAK mutations. Data are displayed as whisker plots of 25th to 75th percentiles with means (central bars) and ranges (whiskers). The dashed horizontal line represents normalized...
basal phosphorylation for each phosphoprotein. Stimulation with IL-7 (yellow bars) had no effect on phosphorylation in CRLF2wt JAKwt (N = 17), CRLF2r JAKwt (N = 12), or CRLF2r JAKmut (N = 12) ALL samples. TSLP stimulation (pink bars) induced pSTAT5 and pS6 in the CRLF2r samples regardless of concomitant JAK mutations (p < 0.05), but has no effect on CRLF2wt samples. XL019 (orange bars) inhibited phosphorylation below basal levels only for pS6 in the CRLF2r JAKmut subset (p = 0.013). Unlike in MUTZ5 cells, TSLP stimulation did not induce pERK significantly in these samples. * = p < 0.05.

Figure 3. *In vitro* stimulation of CRLF2r ALL with TSLP induced phosphorylation of STAT5 and PI3K pathway proteins and, to a lesser extent, ERK. Phosphorylation of signaling proteins was abrogated by specific STIs.

A. Hypothetical schema of aberrant signal transduction mediated by the TSLPR heterodimer in CRLF2r ALL and strategies for targeting the perturbed signaling nodes with STIs.

B. Phosphoflow cytometry analysis of fixed and permeabilized MUTZ5 cells demonstrated increased phosphorylation of JAK2, STAT5, ERK, Akt, S6, and eIF4E following stimulation with TSLP. Inhibition of basal and/or TSLP-induced phosphorylation of relevant proteins was observed with specific STIs.

C. Western blotting analysis of MUTZ5. Cells demonstrated constitutive phosphorylation of S6 and 4EBP1. TSLP-induced phosphorylation of signal transduction proteins and abrogation of phosphorylation by specific STIs was generally concordant with phosphoflow cytometry results in (A), although more pronounced TSLP-induced pERK was observed by Western blotting.

D. Cytotoxicity assays of MUTZ5 and RCH-ACV cell lines treated with STIs. Cells were treated with the specified STIs for 72 hours prior to performing MTT assays. Ruxolitinib induced moderate dose-dependent cytotoxicity in MUTZ5. The PI3K/mTOR STIs induced dose-
dependent cytotoxicity in both cell lines. Data are normalized to DMSO controls (black). Red = 10 nM, yellow = 100 nM, green = 500 nM, blue = 1000 nM of each STI. Rux = ruxolitinib. Rapa = rapamycin.

Figure 4. Expanded analysis of primary CRLF2r ALL samples demonstrates inhibition of JAK/STAT and PI3K pathway signaling. Analysis of JAK/STAT, PI3K/mTOR, and MAPK pathway STIs in 29 CRLF2wt (A) and CRLF2r (B) primary human leukemias. Data are displayed as whisker plots of 25th to 75th percentiles with means (central bars) and ranges (whiskers). The dashed horizontal line represents normalized basal phosphorylation for each phosphoprotein. Pink = TSLP, striped red = ruxolitinib, solid red = ruxolitinib + TSLP, striped green = rapamycin, solid green = rapamycin + TSLP, striped blue = PI103, solid blue = PI103 + TSLP, striped purple = PP242, solid purple = PP242 + TSLP, striped grey = PD901, solid grey = PD901 + TSLP. Minimal effects of TSLP stimulation or STIs were observed for the CRLF2wt samples. TSLP stimulation induced pSTAT5, pAkt, pS6, p4EBP1, peIF4E, and pERK in the CRLF2r samples (p < 0.05), and incubation with ruxolitinib resulted in continued inhibition of all above phosphoproteins (p < 0.05). PI103 inhibited TSLP-induced pAkt, pS6, and pERK (p < 0.05). PP242 abrogated TSLP-induced pAkt, pS6, and peIF4E (p < 0.05). PD901 inhibited TSLP-induced pS6, peIF4E, and pERK (p < 0.05).
Figure 1

A

CRLF2 wild-type  P2RY8-CRLF2  IGH@-CRLF2  CRLF2 F232C

Maximal Intensity

TSLPR

Maximal Intensity

CD127

B

MUTZ5

RCH-ACV

CD127

TSLPR

CD132

C

% Proliferation

MUTZ5  RCH-ACV

D

Basal

TSLP 10 ng/mL

TSLP 25 ng/mL

TSLP 50 ng/mL

TSLP 100 ng/mL

pSTAT5
Figure 2

A

Basal
IL-7
TSLP
XL019

Pervanadate

pJAK2
pSTAT5
pS6
pERK

B

C

CRLF2wt JAKwt

CRLF2r JAKwt

CRLF2r JAKmut

IL-7
TSLP
XL019

IL-7
TSLP
XL019

IL-7
TSLP
XL019

Fold-Change in Phosphorylation

pSTAT5
pS6
pERK
Figure 3

A

JAK Inhibition
XL019
Ruxolitinib

CRL2
TSLP

C

STI
TSLP
Pervanadate

Ruxolitinib
Rapamycin
PI103
PP242
PD901

pSTAT5
pAkt
pS6
p4EBP1
peIF4E

pERK

B

Basal
TSLP
Ruxolitinib
Ruxolitinib TSLP
Rapamycin
Rapamycin TSLP
PI103
PI103 TSLP
PP242
PP242 TSLP
PD901
PD901 TSLP
Pervanadate

pJAK2
pSTAT5
pAkt
pS6
p4EBP1
peIF4E
pERK

D

MUTZ5
RCH-ACV

% Growth of Control

DMSO
Ruxolitinib
Rapamycin
PI103
PP242
PD901
Rux + Rapa

10 nM
100 nM
500 nM
1000 nM
Figure 4

A  CRLF2<sub>wt</sub>

Fold-Change in Phosphorylation

<table>
<thead>
<tr>
<th>Protein</th>
<th>pSTAT5</th>
<th>pAkt</th>
<th>pS6</th>
</tr>
</thead>
<tbody>
<tr>
<td>p4EBP1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>peIF4E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pERK</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B  CRLF2<sub>r</sub>

Fold-Change in Phosphorylation

<table>
<thead>
<tr>
<th>Protein</th>
<th>pSTAT5</th>
<th>pAkt</th>
<th>pS6</th>
</tr>
</thead>
<tbody>
<tr>
<td>p4EBP1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>peIF4E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pERK</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia

Sarah K. Tasian, Michelle Y. Doral, Michael J. Borowitz, Brent L. Wood, I-Ming Chen, Richard C. Harvey, Julie M. Gastier-Foster, Cheryl L. Willman, Stephen P. Hunger, Charles G. Mullighan and Mignon L. Loh